April 11, 2025
By the late 1990s, annual cases of measles in the United States dwindled to a few dozen, down from more than 27,000 in 1990. However, the […]
April 10, 2025
TOPLINE: Treatment with delgocitinib cream, a topical pan-Janus kinase inhibitor, resulted in a significant improvement in health-related quality of life in patients with moderate to severe […]
April 9, 2025
TOPLINE: Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. […]
April 4, 2025
ORLANDO, Fla. — Beyond appropriate use criteria for Mohs surgery outlined by a multidisciplinary ad hoc task force in 2012, choice of treatment for superficial skin […]
April 4, 2025
TOPLINE: Most survey respondents were unaware of US Food and Drug Administration (FDA)-approved treatments for hidradenitis suppurativa (HS), and only 18% were satisfied with their current […]
April 3, 2025
ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that […]
April 3, 2025
TOPLINE: Ruxolitinib cream was well tolerated, and the application of the cream led to clinically meaningful repigmentation in patients with vitiligo at 1 year, regardless of […]
April 3, 2025
TOPLINE: In a review of pregnant patients with pityriasis rosea (PR), 19% experienced unfavorable outcomes, which were higher in cases that occurred before 15 weeks gestation. […]
April 2, 2025
TOPLINE: Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly […]